A real-life case shows how a microbiota-based therapy can provide an effective alternative when conventional antibiotics treatments fail.
At Mikrobiomik, we are committed to turning scientific innovation into real solutions for patients. This commitment is reflected in a clinical case recently reported by El Mundo, describing the evolution of Raúl, an adolescent with ulcerative colitis whose condition was severely complicated by a recurrent Clostridioides difficile infection. After multiple relapses and failure to respond to standard antibiotic treatments, major surgery became a serious possibility.
The intervention of Dr. Iago Rodríguez-Lago, gastroenterologist at Galdakao Hospital and a leading specialist in inflammatory bowel disease, was decisive in changing the course of the disease. Given the severity of the case, the medical team decided to administer MBK-01, a microbiota-based biological therapy, accessed through a compassionate use program.
The outcome was remarkable: the infection was resolved in less than 48 hours, avoiding colectomy and allowing the patient to recover progressively. As highlighted by Dr. Rodríguez-Lago, MBK-01 has shown high efficacy even in complex patients who do not respond to conventional antibiotic treatments, significantly improving their quality of life.
This real-world clinical case highlights the value of MBK-01 as an innovative, non-invasive, microbiota-based therapeutic option and underscores the potential of microbiota therapies to transform the management of severe and recurrent infections.
To read the full article, click the link below
